1004761-68-5Relevant articles and documents
TRANSITION METAL-COMPLEX CATALYSTS HAVING APPENDED GROUP 13 LEWIS ACIDS AND RELATED POLYMERIZATION METHODS
-
Paragraph 0118; 0122, (2021/11/06)
Compositions may comprise symmetrical and asymmetrical pyridine-containing transition metal-complexes having appended group (13) Lewis acids positioned on the pyridine-containing ligands of the transition metal-complex such that the group (13) Lewis acid
Novel cyclic bicarbodiimide compound and preparation method of novel cyclic bicarbodiimide compound
-
, (2017/08/29)
The invention relates to a novel cyclic bicarbodiimide compound (I) and a preparation method of the novel cyclic bicarbodiimide compound. Compared with monocarbodiimide, the novel cyclic bicarbodiimide compound has a higher molecular weight and a higher melting point; the disadvantage that the monocarbodiimide is easily transferred outward from compounds including polyester, polyurethane and like at high temperature is overcome; the anti-hydrolytic property of a material is improved; meanwhile, the defects that an existing bicarbodiimide compound is easily irregularly curled, easily forms a rubber state at room temperature and is not easy to crystallize and purify are overcome; the anti-hydrolytic effect is good and the bicarbodiimide compound has a good anti-hydrolytic property; the service life of a polyester material is improved; the bicarbodiimide compound can be used as an anti-hydrolytic stabilizer and is used for polyurethane and polyester elastomers, and especially can be used for photovoltaic industry, biodegradable materials and the like. The formula (I) is shown in the description.
NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
-
Paragraph 0428; 0759-0760, (2013/10/07)
The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.